An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system

John W. Stevenson, Alicia B. Minns, Craig Smollin, Timothy E Albertson, F. Lee Cantrell, Christian Tomaszewski, Richard F. Clark

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: Characterize clinical presentations and outcomes of dabigatran and rivaroxaban exposures reported to a poison control system. Methods: Data for cases of dabigatran and rivaroxaban exposures called into the California Poison Control System from January 2011 to July 2013 were collected. Data collected included patient demographics, type of exposure, medication, dosage, vital signs, laboratory values, interventions, outcomes, and disposition. Exclusion criteria included confirmed nonexposures or miscoded cases. Results: A total of 56 cases were identified, with 7 excluded, leaving 37 dabigatran and 12 rivaroxaban cases. Children age 12 years or less accounted for 5 dabigatran and 2 rivaroxaban cases. Bleeding was reported in 15 dabigatran cases. There were 4 cases of acute self-harm overdose with dabigatran ranging from 1800 to 3900 mg. Mild bleeding was reported in only one of these overdose cases. There were 2 fatal hemorrhages in dabigatran cases, both in chronic therapeutic dosing. Bleeding was reported in 5 rivaroxaban cases, all in patients with chronic exposure; no deaths were reported. There were no adverse outcomes in pediatric patients. Coagulation parameters did not correlate well with bleeding. Conclusions: In our series, the greatest risk of adverse events was in patients chronically taking these agents, irrespective of excess dosing. Acute self-harm ingestions and accidental pediatric ingestions had few adverse effects, although massive overdose can lead to abnormal coagulation studies. It does not appear that single low-dose ingestions of either medication will lead to clinically significant bleeding. It may be possible to manage some pediatric exposures and most accidental ingestions with observation.

Original languageEnglish (US)
Pages (from-to)1077-1084
Number of pages8
JournalAmerican Journal of Emergency Medicine
Volume32
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Poisons
Hemorrhage
Eating
Pediatrics
Vital Signs
Dabigatran
Rivaroxaban
Observation
Demography

ASJC Scopus subject areas

  • Emergency Medicine
  • Medicine(all)

Cite this

An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system. / Stevenson, John W.; Minns, Alicia B.; Smollin, Craig; Albertson, Timothy E; Cantrell, F. Lee; Tomaszewski, Christian; Clark, Richard F.

In: American Journal of Emergency Medicine, Vol. 32, No. 9, 2014, p. 1077-1084.

Research output: Contribution to journalArticle

Stevenson, John W. ; Minns, Alicia B. ; Smollin, Craig ; Albertson, Timothy E ; Cantrell, F. Lee ; Tomaszewski, Christian ; Clark, Richard F. / An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system. In: American Journal of Emergency Medicine. 2014 ; Vol. 32, No. 9. pp. 1077-1084.
@article{4a7ab6860eec4c278111f5722903bc9c,
title = "An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system",
abstract = "Objective: Characterize clinical presentations and outcomes of dabigatran and rivaroxaban exposures reported to a poison control system. Methods: Data for cases of dabigatran and rivaroxaban exposures called into the California Poison Control System from January 2011 to July 2013 were collected. Data collected included patient demographics, type of exposure, medication, dosage, vital signs, laboratory values, interventions, outcomes, and disposition. Exclusion criteria included confirmed nonexposures or miscoded cases. Results: A total of 56 cases were identified, with 7 excluded, leaving 37 dabigatran and 12 rivaroxaban cases. Children age 12 years or less accounted for 5 dabigatran and 2 rivaroxaban cases. Bleeding was reported in 15 dabigatran cases. There were 4 cases of acute self-harm overdose with dabigatran ranging from 1800 to 3900 mg. Mild bleeding was reported in only one of these overdose cases. There were 2 fatal hemorrhages in dabigatran cases, both in chronic therapeutic dosing. Bleeding was reported in 5 rivaroxaban cases, all in patients with chronic exposure; no deaths were reported. There were no adverse outcomes in pediatric patients. Coagulation parameters did not correlate well with bleeding. Conclusions: In our series, the greatest risk of adverse events was in patients chronically taking these agents, irrespective of excess dosing. Acute self-harm ingestions and accidental pediatric ingestions had few adverse effects, although massive overdose can lead to abnormal coagulation studies. It does not appear that single low-dose ingestions of either medication will lead to clinically significant bleeding. It may be possible to manage some pediatric exposures and most accidental ingestions with observation.",
author = "Stevenson, {John W.} and Minns, {Alicia B.} and Craig Smollin and Albertson, {Timothy E} and Cantrell, {F. Lee} and Christian Tomaszewski and Clark, {Richard F.}",
year = "2014",
doi = "10.1016/j.ajem.2014.04.031",
language = "English (US)",
volume = "32",
pages = "1077--1084",
journal = "American Journal of Emergency Medicine",
issn = "0735-6757",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system

AU - Stevenson, John W.

AU - Minns, Alicia B.

AU - Smollin, Craig

AU - Albertson, Timothy E

AU - Cantrell, F. Lee

AU - Tomaszewski, Christian

AU - Clark, Richard F.

PY - 2014

Y1 - 2014

N2 - Objective: Characterize clinical presentations and outcomes of dabigatran and rivaroxaban exposures reported to a poison control system. Methods: Data for cases of dabigatran and rivaroxaban exposures called into the California Poison Control System from January 2011 to July 2013 were collected. Data collected included patient demographics, type of exposure, medication, dosage, vital signs, laboratory values, interventions, outcomes, and disposition. Exclusion criteria included confirmed nonexposures or miscoded cases. Results: A total of 56 cases were identified, with 7 excluded, leaving 37 dabigatran and 12 rivaroxaban cases. Children age 12 years or less accounted for 5 dabigatran and 2 rivaroxaban cases. Bleeding was reported in 15 dabigatran cases. There were 4 cases of acute self-harm overdose with dabigatran ranging from 1800 to 3900 mg. Mild bleeding was reported in only one of these overdose cases. There were 2 fatal hemorrhages in dabigatran cases, both in chronic therapeutic dosing. Bleeding was reported in 5 rivaroxaban cases, all in patients with chronic exposure; no deaths were reported. There were no adverse outcomes in pediatric patients. Coagulation parameters did not correlate well with bleeding. Conclusions: In our series, the greatest risk of adverse events was in patients chronically taking these agents, irrespective of excess dosing. Acute self-harm ingestions and accidental pediatric ingestions had few adverse effects, although massive overdose can lead to abnormal coagulation studies. It does not appear that single low-dose ingestions of either medication will lead to clinically significant bleeding. It may be possible to manage some pediatric exposures and most accidental ingestions with observation.

AB - Objective: Characterize clinical presentations and outcomes of dabigatran and rivaroxaban exposures reported to a poison control system. Methods: Data for cases of dabigatran and rivaroxaban exposures called into the California Poison Control System from January 2011 to July 2013 were collected. Data collected included patient demographics, type of exposure, medication, dosage, vital signs, laboratory values, interventions, outcomes, and disposition. Exclusion criteria included confirmed nonexposures or miscoded cases. Results: A total of 56 cases were identified, with 7 excluded, leaving 37 dabigatran and 12 rivaroxaban cases. Children age 12 years or less accounted for 5 dabigatran and 2 rivaroxaban cases. Bleeding was reported in 15 dabigatran cases. There were 4 cases of acute self-harm overdose with dabigatran ranging from 1800 to 3900 mg. Mild bleeding was reported in only one of these overdose cases. There were 2 fatal hemorrhages in dabigatran cases, both in chronic therapeutic dosing. Bleeding was reported in 5 rivaroxaban cases, all in patients with chronic exposure; no deaths were reported. There were no adverse outcomes in pediatric patients. Coagulation parameters did not correlate well with bleeding. Conclusions: In our series, the greatest risk of adverse events was in patients chronically taking these agents, irrespective of excess dosing. Acute self-harm ingestions and accidental pediatric ingestions had few adverse effects, although massive overdose can lead to abnormal coagulation studies. It does not appear that single low-dose ingestions of either medication will lead to clinically significant bleeding. It may be possible to manage some pediatric exposures and most accidental ingestions with observation.

UR - http://www.scopus.com/inward/record.url?scp=84921649239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921649239&partnerID=8YFLogxK

U2 - 10.1016/j.ajem.2014.04.031

DO - 10.1016/j.ajem.2014.04.031

M3 - Article

VL - 32

SP - 1077

EP - 1084

JO - American Journal of Emergency Medicine

JF - American Journal of Emergency Medicine

SN - 0735-6757

IS - 9

ER -